New drug cocktail aims to shrink prostate tumors before surgery

NCT ID NCT05873192

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study is testing whether adding talazoparib to standard hormone therapy and enzalutamide can help men with prostate cancer that has spread to lymph nodes. About 30 participants will take the drug combination before having their prostate removed. The goal is to see if the treatment is safe and effective at controlling the cancer before surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: talazoparib and enzalutamide (drugs)
What this could lead to: If successful, this could lead to a more effective treatment option for men with prostate cancer that has spread to lymph nodes, potentially improving outcomes before surgery.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination may cause side effects like fatigue or blood issues, and it's not yet proven to work better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.